Lumira Ventures
Lumira Ventures is a venture capital firm based in Toronto, Ontario, specializing in investments in emerging, mid, and late-stage companies within the healthcare and life sciences sectors. Founded in 2007, the firm primarily focuses on biotechnology, biopharmaceuticals, medical devices, digital health, and consumer health companies, with a strong emphasis on opportunities in North America, particularly Canada and the United States. Lumira Ventures typically invests between 5 million and 15 million in its portfolio companies, which currently includes over 30 active investee firms. The firm is dedicated to maximizing the value of its investments through active board participation and facilitating access to additional funding sources, strategic partners, and market opportunities. With a track record of investing in more than 100 healthcare companies since its inception, Lumira Ventures aims to support entrepreneurial management teams in addressing significant unmet needs within the healthcare landscape.
AmacaThera Inc. is a biotechnology company based in Toronto, Canada, established in 2016. The company specializes in developing and commercializing an innovative injectable hydrogel platform technology aimed at enhancing medical treatments. This technology is designed to localize and sustain drug delivery, thereby improving patient outcomes across various therapeutic areas. AmacaThera's hydrogel consists of a reversible and fast-gelling physical blend of hyaluronan and methylcellulose, which liquefies under force. This unique formulation assists healthcare providers in reducing post-operative pain for patients, showcasing the potential of AmacaThera's approach in addressing significant medical needs.
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatment options for heart failure and associated cardiovascular conditions. The company's primary product is the Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach. This innovative device reshapes the mitral valve to reduce regurgitation, enabling less invasive procedures for patients. Founded in 2000 and headquartered in Kirkland, Washington, Cardiac Dimensions also has operations in Sydney, Australia, and Offenbach, Germany.
AmacaThera Inc. is a biotechnology company based in Toronto, Canada, established in 2016. The company specializes in developing and commercializing an innovative injectable hydrogel platform technology aimed at enhancing medical treatments. This technology is designed to localize and sustain drug delivery, thereby improving patient outcomes across various therapeutic areas. AmacaThera's hydrogel consists of a reversible and fast-gelling physical blend of hyaluronan and methylcellulose, which liquefies under force. This unique formulation assists healthcare providers in reducing post-operative pain for patients, showcasing the potential of AmacaThera's approach in addressing significant medical needs.
Bardy Diagnostics, Inc. is a medical device company that specializes in the development and manufacturing of cardiac monitoring solutions, primarily focused on arrhythmia detection. Its flagship product, the Carnation Ambulatory Monitor (CAM), is a lightweight, discreet cardiac patch that can be worn comfortably for up to seven days, even during physical activities like exercise or showering. The CAM is designed with a unique hourglass shape to enhance comfort, particularly for female patients. Complementing the monitor is the BDxCONNECT patient management system, which allows healthcare providers to create and manage patient reports efficiently. By utilizing innovative P-wave centric ECG detection technology, Bardy Diagnostics aims to improve clinical management and outcomes for patients and their physicians. Founded in 2013, the company is headquartered in Seattle, Washington, with additional offices in Houston, Texas, and New Providence, New Jersey.
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatment options for heart failure and associated cardiovascular conditions. The company's primary product is the Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach. This innovative device reshapes the mitral valve to reduce regurgitation, enabling less invasive procedures for patients. Founded in 2000 and headquartered in Kirkland, Washington, Cardiac Dimensions also has operations in Sydney, Australia, and Offenbach, Germany.
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatment options for heart failure and associated cardiovascular conditions. The company's primary product is the Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach. This innovative device reshapes the mitral valve to reduce regurgitation, enabling less invasive procedures for patients. Founded in 2000 and headquartered in Kirkland, Washington, Cardiac Dimensions also has operations in Sydney, Australia, and Offenbach, Germany.
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatment options for heart failure and associated cardiovascular conditions. The company's primary product is the Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach. This innovative device reshapes the mitral valve to reduce regurgitation, enabling less invasive procedures for patients. Founded in 2000 and headquartered in Kirkland, Washington, Cardiac Dimensions also has operations in Sydney, Australia, and Offenbach, Germany.
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatment options for heart failure and associated cardiovascular conditions. The company's primary product is the Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach. This innovative device reshapes the mitral valve to reduce regurgitation, enabling less invasive procedures for patients. Founded in 2000 and headquartered in Kirkland, Washington, Cardiac Dimensions also has operations in Sydney, Australia, and Offenbach, Germany.
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatment options for heart failure and associated cardiovascular conditions. The company's primary product is the Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach. This innovative device reshapes the mitral valve to reduce regurgitation, enabling less invasive procedures for patients. Founded in 2000 and headquartered in Kirkland, Washington, Cardiac Dimensions also has operations in Sydney, Australia, and Offenbach, Germany.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.